Previous close | 10.43 |
Open | 10.40 |
Bid | 10.57 x 200 |
Ask | 10.70 x 300 |
Day's range | 10.17 - 10.86 |
52-week range | 1.52 - 12.35 |
Volume | |
Avg. volume | 204,319 |
Market cap | 346.971M |
Beta (5Y monthly) | 1.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.16 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time
John Boniface, the Chief Scientific Officer of Sera Prognostics Inc (NASDAQ:SERA), has sold 77,136 shares of the company on March 28, 2024, according to a recent SEC Filing.
John Boniface, Chief Scientific Officer of Sera Prognostics Inc (NASDAQ:SERA), has sold 22,163 shares of the company on March 25, 2024, according to a recent SEC Filing.